title: Ketogenic diet in patients with myoclonic-astatic epilepsy.
abstract: For more than 80 years, the ketogenic diet has been used as an alternative to antiepileptic drugs for patients with refractory epilepsy. Myoclonic-astatic epilepsy in early childhood is one of the malignant epilepsy syndromes that often proves refractory to antiepileptic drugs treatment. Objective. In this prospective study we assess the efficacy and tolerability of the ketogenic diet in patients with myoclonic-astatic epilepsy. Material and methods. Between March 1, 1990 and August 31, 2004, 30 patients who met diagnostic criteria of myoclonic-astatic epilepsy were seen at our department. Eleven of them were placed on the ketogenic diet using the Hopkins protocol and were followed for a minimum of 18 months. Results. The children had previously received a mean of 5.2 different antiepileptic drugs and were on a mean of 2.2 antiepileptic drugs when the diet was started. Eighteen months after initiating the diet, six of the patients (54.5%) remained on the diet. Two patients (18%) were seizure-free, two (18%) had a 75-99% decrease in seizures, and the remaining two children (18%) had a 50% to 74% decrease in seizures. The first two patients were tapered off the diet after remaining seizure-free, without antiepileptic drugs for several years. In the two patients who had sporadic seizures, antiepileptic drugs were reduced to one, and in the last two the seizure frequency was significantly reduced. No differences in seizure control were found when compared for age, sex, or seizure type. Five of our patients discontinued the ketogenic diet in less than 3 months (four because of lack of effectiveness and one because of persistent vomiting). Conclusion. The ketogenic diet is a promising therapy for patients with myoclonic-astatic epilepsy, with over half the children showing a > 50% reduction in seizures, and seizure-freedom in 18%. In drug resistant cases of myoclonic-astatic epilepsy, the diet should be considered early in the course of this syndrome and not as a last resort.
authors.affiliation: Servicio de Neurología, Hospital de Pediatría "Prof Dr Juan P Garrahan", Buenos Aires, Argentina. rhcaraballo@arnet.com.ar
authors.forename: Roberto Horacio
authors.initials: RH
authors.lastname: Caraballo
authors.forename: Ricardo Oscar
authors.initials: RO
authors.lastname: Cersósimo
authors.forename: Diego
authors.initials: D
authors.lastname: Sakr
authors.forename: Araceli
authors.initials: A
authors.lastname: Cresta
authors.forename: Nidia
authors.initials: N
authors.lastname: Escobal
authors.forename: Natalio
authors.initials: N
authors.lastname: Fejerman
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004041:Dietary Fats / Q000008:administration & dosage*; D004831:Epilepsies, Myoclonic / Q000178:diet therapy* / Q000188:drug therapy; D006801:Humans; D007659:Ketones / Q000378:metabolism*; D007662:Ketosis / Q000209:etiology / Q000378:metabolism*; D011446:Prospective Studies; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D004041:Dietary Fats; D007659:Ketones